Monitoring parameters in the management of patients with tubo-ovarian complexes

International Journal of Gynecology and Obstetrics

Volumn 64, Issue 3, 1999, Pages 273-279

  Reljic M ^a   But, I ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

CA 125; CRP; Inflammatory parameters; TOC; Ultrasound

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; CLINDAMYCIN; GENTAMICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE COURSE; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; OVARY TUMOR; PATIENT MONITORING; PRIORITY JOURNAL; TUMOR VOLUME; UTERINE TUBE TUMOR;

EID: 0032955491     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(98)00260-4     Document Type: Article

References (18)

1. Soper DE. Upper genital tract infections. In: Copelands LJ, editor. Textbook of gynecology. Philadelphia: W.B. Saunders Company, 1993:517-530.
2. Reed SD, Landers DV, Sweet RL. Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum beta-lactam agents versus clindamycin-containing regimens. Am J Obstet Gynecol 1991;164:1556-1562.
3. Landers DV, Wolner-Hanssen P, Paavonen J et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol 1991;164:849-857.
4. Miettinen AK, Heinonen PK, Laippala P, Paavonen J. Test performance of erythrocite sedimentation rate and C-reactive protein in assessing the severity of acute pelvic inflammatory disease. Am J Obstet Gynecol 1993;169:1143-1149.
5. Lehtinen M, Laine S, Heinonen PK et al. Serum C-reactive protein determination in acute pelvic inflammatory disease. Am J Obstet Gynecol 1986;154:158-159.
6. Moley HK, Massad SL, Mutch GD. Pelvic inflammatory disease: correlation of severity with CA-125 levels. J Reprod Med 1996;41:341-346.
7. Mercer LJ, Hajj SN, Ismail MA, Block BS. Use of CRP to predict the outcome and management of tuboovarian abscesses. J Reprod Med 1988;33:164-167.
8. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR 1997;46(RR-10):52.
9. Fleischer AC, Entman SS. Differential diagnosis of pelvic masses. In: Chervenak FA, Isaacson GC, Campbell S, editors. Ultrasound in obstetrics and gynecology. Boston: Little, Brown, 1993:1650.
10. ACOG Technical Bulletin. Antimicrobial therapy for gynecologic infection. Int J Gynaecol Obstet 1992;38:131-139.
11. Reljič M, Gorišek B. C-reactive protein and the treatment of pelvic inflammatory disease. Int J Gynaecol Obstet 1998;60:143-150.
12. Angerman NS, Evans MI, Moravec WD, Schumacher GF, Hajj SN. CRP in evaluation of antibiotic therapy for pelvic infection. J Reprod Med 1980;25:63-66.
13. Brumsted JR, Mead PB, Gibson M. Serum concentration of protein CA125 in women with pelvic inflammatory disease. Sex Trans Dis 1988;15:144-147.
14. Caspi B, Zalel Y, Or Y, Dayan YB, Appelman Z, Katz Z. Sonographically guided aspiration: an alternative therapy for tubo-ovarian abscess. Ultrasound Obstet Gynecol 1996;7:439-442.
15. Schmidt-Rhode P, Schulz K-D, Sturm G, Prinz H. C-reactive protein is a marker for the diagnosis of adnexitis. Int J Gynaecol Obstet 1990;32:133-139.
16. Pepys MB. C-reactive protein fifty years on. Lancet 1981;43:653-657.
17. Kaplan MH. C-reactive protein: relation to disease and pathological significance. Ann N J Acad Sci 1982; 389:419-421.
18. Mozas J, Castilla JA, Jimena P, Gil T, Acebal M, Herruzo AJ. Serum CA-125 in the diagnosis of acute pelvic inflammatory disease. Int J Gynaecol Obstet 1994;44:53-57.